microRNA Replacement Therapy
Press Releases

 
Press Releases
Date Title and Summary View
11-13-15 Demonstrated confirmed partial responses in liver cancer and melanoma in Phase 1 clinical trial of lead product candidate MRX34 Completed IPO and concurrent private placement in October with aggregate gross proceeds of $65.5 million Strengthened management team with...
11-09-15 Data presented at AACR-NCI-EORTC International Conference AUSTIN, Texas--(BUSINESS WIRE)-- Mirna Therapeutics, Inc. (Nasdaq:MIRN), a clinical-stage biopharmaceutical company developing a broad pipeline of microRNA-based oncology therapeutics, today announced the presentation of interim ...
10-27-15 AUSTIN, Texas--(BUSINESS WIRE)-- Mirna Therapeutics, Inc. (Nasdaq:MIRN), a clinical-stage biopharmaceutical company developing a broad pipeline of microRNA-based oncology therapeutics, announced the appointment of Dr. Miguel Barbosa, Ph.D. as Executive Vice President and Chief Scientific Officer. ...
10-06-15 AUSTIN, Texas--(BUSINESS WIRE)-- Mirna Therapeutics, Inc. (Nasdaq:MIRN), a clinical-stage biopharmaceutical company developing a broad pipeline of microRNA-based oncology therapeutics, today announced the closing of its initial public offering (IPO) of 6,250,000 shares of common stock at a public offering ...
10-01-15 AUSTIN, Texas - October 1, 2015 - Mirna Therapeutics, Inc., a clinical stage biopharmaceutical company developing a broad pipeline of microRNA based oncology therapeutics, today announced the pricing of its initial public offering of 6,250,000 shares of common stock at a public offering price of $7.00 per share. The shares are expected to...
09-16-15
04-30-15
04-21-15
11-19-14
09-26-14
Page: FirstPrevious
3
... NextLast
= add release to Briefcase
© 2017 Mirna Therapeutics, Inc. All Rights Reserved.